Vepured

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

recombinant Verotoxin 2e of E. coli

Disponible depuis:

Laboratorios Hipra, S.A.

Code ATC:

QI09AB02

DCI (Dénomination commune internationale):

E. coli verotoxoid vaccine (inactivated recombinant)

Groupe thérapeutique:

Pigs

Domaine thérapeutique:

Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium, Immunologicals for suidae

indications thérapeutiques:

Active immunisation of piglets from 2 days of age to prevent mortality and reduce clinical signs of oedema disease (caused by verotoxin 2e produced by E. coli) and to reduce the loss of daily weight gain during the finishing period in the face of infections with verotoxin 2e producing E. coli until slaughter from 164 days of age.

Descriptif du produit:

Revision: 3

Statut de autorisation:

Authorised

Date de l'autorisation:

2017-08-17

Notice patient

                                10
PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE
PACKAGE
Cardboard box with vial of 10 x10 doses.
Cardboard box with vials of 10, 50, 100 or 250 doses.
Vial of 100 or 250 doses.
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
VEPURED suspension for injection for pigs
recombinant verotoxin 2e of
_E. coli_
2.
STATEMENT OF ACTIVE SUBSTANCES
Each dose of 1 ml contains:
Recombinant verotoxin 2e of
_E. coli_
................................................................ RP
≥ 1.50.
3.
PHARMACEUTICAL FORM
Suspension for injection.
4.
PACKAGE SIZE
10 doses (10 ml)
50 doses (50 ml)
100 doses (100 ml)
250 doses (250 ml)
10 x 10 doses (10 ml)
5.
TARGET SPECIES
Pigs.
6.
INDICATION(S)
7.
METHOD AND ROUTE(S) OF ADMINISTRATION
Intramuscular use.
Read the package leaflet before use.
8.
WITHDRAWAL PERIOD(S)
Withdrawal period: Zero days.
11
9.
SPECIAL WARNING(S), IF NECESSARY
Read the package leaflet before use.
10.
EXPIRY DATE
EXP {month/year}
Once broached use within 10 hours.
11.
SPECIAL STORAGE CONDITIONS
Store and transport refrigerated.
Do not freeze.
Protect from light.
12.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR
WASTE MATERIALS, IF ANY
Disposal: read package leaflet.
13.
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE
For animal treatment only. To be supplied only on veterinary
prescription.
14.
THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
Keep out of the sight and reach of children.
15.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN
16.
MARKETING AUTHORISATION NUMBER(S)
EU/2/17/214/001 (10 doses (10 ml))
EU/2/17/214/002 (50 doses (50 ml))
EU/2/17/214/003 (100 doses (100 ml))
EU/2/17/214/004 (250 doses (250 ml))
EU/2/17/214/005 (10 x 10 doses (10 ml))
17.
MANUFACTURER’S BATCH NUMBER
Batch
12
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Vial of 10 or 50 doses
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
VEPURED sus
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
VEPURED suspension for injection for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml contains:
ACTIVE SUBSTANCE:
Recombinant verotoxin 2e of
_E. coli_
................................................................ RP*
≥ 1.50
* RP – relative potency (ELISA)
ADJUVANTS:
Aluminium hydroxide (Al
3+
)
...........................................................................
2.117 mg
DEAE-dextran
......................................................................................................
10 mg.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
Whitish suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of piglets from 2 days of age to prevent mortality
and reduce clinical signs of
oedema disease (caused by verotoxin 2e produced by
_E. coli_
) and to reduce the loss of daily weight
gain during the finishing period in the face of infections with
verotoxin 2e producing
_E. coli _
until
slaughter from 164 days of age.
Onset of immunity:
21 days after vaccination.
Duration of immunity:
112 days after vaccination.
4.3
CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substance, to
the adjuvants or to any of the
excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Not applicable.
3
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
Not applicable.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Very common adverse reactions:
- Mild inflammation at the injection site (< 5 cm in diameter) that
typically resolves within three
days post-vaccination without treatment.
- Mild depression during the day of vaccination.
- Temperature rise of maximum 1.1 °C was observed. Temperatures
returned to nor
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation bulgare 18-09-2017
Notice patient Notice patient espagnol 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation espagnol 18-09-2017
Notice patient Notice patient tchèque 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation tchèque 18-09-2017
Notice patient Notice patient danois 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation danois 18-09-2017
Notice patient Notice patient allemand 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation allemand 18-09-2017
Notice patient Notice patient estonien 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation estonien 18-09-2017
Notice patient Notice patient grec 05-11-2021
Notice patient Notice patient français 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation français 18-09-2017
Notice patient Notice patient italien 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation italien 18-09-2017
Notice patient Notice patient letton 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation letton 18-09-2017
Notice patient Notice patient lituanien 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation lituanien 18-09-2017
Notice patient Notice patient hongrois 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation hongrois 18-09-2017
Notice patient Notice patient maltais 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation maltais 18-09-2017
Notice patient Notice patient néerlandais 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation néerlandais 18-09-2017
Notice patient Notice patient polonais 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation polonais 18-09-2017
Notice patient Notice patient portugais 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation portugais 18-09-2017
Notice patient Notice patient roumain 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation roumain 18-09-2017
Notice patient Notice patient slovaque 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation slovaque 18-09-2017
Notice patient Notice patient slovène 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation slovène 18-09-2017
Notice patient Notice patient finnois 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation finnois 18-09-2017
Notice patient Notice patient suédois 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation suédois 18-09-2017
Notice patient Notice patient norvégien 05-11-2021
Notice patient Notice patient islandais 05-11-2021
Notice patient Notice patient croate 05-11-2021
Rapport public d'évaluation Rapport public d'évaluation croate 18-09-2017

Rechercher des alertes liées à ce produit

Afficher l'historique des documents